Other languages Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Delayed Nasdaq Stockholm Other stock markets 03:55:40 2024-05-29 am EDT			5-day change	1st Jan Change
73 ^SEK	-3.18%		+24.57%	+82.50%

May. 23	Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	CI
May. 20	Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	May. 23
Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	May. 20
Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	Apr. 22
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	Feb. 12
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	Feb. 12
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR	Feb. 07
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage	Nov. 21
Xspray Pharma AB Through HyNap? technology Announces Results from Drug Interaction Studies	Nov. 08
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Xspray Pharma AB Announces Nomination Committee for the Annual General Meeting 2024	23-10-24
Xspray Pharma Names Chief Commercial Officer	23-09-15
Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer	23-09-15
Xspray Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
US FDA Requests More Data from Xspray Pharma for Dasynoc Drug Candidate; Shares Fall 7%	23-07-11
Xspray Pharma AB Receives Request for Additional Information Concerning Dasynoc from FDA	23-07-11
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
Xspray Pharma AB Auditor Raises 'Going Concern' Doubt	23-03-28
Xspray Pharma AB Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc for the Treatment of Chronic Myeloid Leukemia and Acute Lymphatic Leukemia	23-02-23
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Other languages

Filters